CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 31 enrolled
Drug / intervention
Fasudil Hydrochloride +1 moredrug
Likely dose
Fasudil Hydrochloride 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03404843
NCT03404843Phase 2Completed
CompareCT.gov

Red Blood Cell ATP Release and Vascular Function in Humans

Colorado State University·interventional·Posted Jan 19, 2018·Updated Feb 27, 2020

In Brief

A Phase 2 clinical trial evaluating Fasudil Hydrochloride and Saline for Cardiovascular Diseases. Completed, enrolled 31 participants across 1 site.

Detailed Summary

Previous work demonstrates that the red blood cells of older adults do not release a potent vasodilator (ATP) as well as the red blood cells of younger adults. The investigators are targeting a pathway within the red blood cell using fasudil hydrochloride to determine if both the release of ATP from red blood cells and blood flow responses to low oxygen (hypoxia) and exercise in older adults can be improved.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCardiovascular Diseases
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJan 19, 2018
Enrollment StartJul 14, 2017
Primary CompletionOct 5, 2018
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 8.5 years ago

Interventions

Fasudil Hydrochloridedrug

10 mg/mL vial of fasudil hydrochloride. 6 mL (60 mg) of fasudil hydrochloride are added to a 100 mL saline bag for delivery to subjects.

Salineother

100 mL saline bag.